Company intelligence / Profile preview

Credentis

Zug, Zug, Switzerlandcredent.com ↗

Ownership: Private
Development stage: Commercial

Overview

Clinical trials demonstrate superiority of CURODONT™ REPAIR over fluoride varnish, with:

80% vs.34% caries inactivation rate[5]
4x higher regression of lesions[5]
15x greater decrease in diagnostic signals[5]

Therapeutic areas: OtherInfectious Diseases
Modalities: Self-assembling peptidesBiomimetic mineralization technology
Industry: Biotech

Drug pipeline

1 asset

Curodont

Commercial

Indications: Dental caries, Tooth decay

Partnerships

DentaQuest (US commercialization)[7]University of Leeds (IP foundation)[4]FHNW School of Life Sciences Muttenz[5]Straumann Group (therapeutic collaboration)[3]

Beyond the preview

Go deeper on Credentis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Credentis.